Iloprost Rafarm (Iloprost)

Iloprost acts as a selective agonist of the prostacyclin (IP) receptor on vascular smooth‑muscle cells. By stimulating this receptor, it raises intracellular cyclic‑AMP, causing relaxation of pulmonary arteries, vasodilation, and inhibition of platelet aggregation, which together improve blood flow in affected vascular beds.

The dose of Iloprost Rafarm is individualized and set by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and tolerability. Specific dosing regimens are not provided here and should follow the prescriber’s instructions and local labeling.

Safety data for Iloprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician in consultation with the patient.

To place an order, submit an enquiry on the Iloprost Rafarm product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and clinics worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Iloprost belongs to the prostacyclin analog class, offering potent vasodilation and antiplatelet effects. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, it provides a direct prostacyclin pathway activation. Choice of therapy depends on disease severity, route‑of‑administration preferences, and individual patient response.

Iloprost Rafarm should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, light, and extreme temperature fluctuations to maintain stability and potency.

Iloprost Rafarm is administered by inhalation using a compatible nebulizer device. The patient inhales the prescribed dose as directed by the healthcare provider, typically several times per day, with each inhalation session lasting a few minutes.

The most serious adverse events include severe hypotension, pulmonary edema, significant bleeding, and bronchospasm. Patients should be monitored closely for these reactions, especially during dose initiation and titration, and any signs of serious complications require immediate medical attention.

Iloprost Rafarm is contraindicated in patients with recent hemoptysis, uncontrolled severe hypotension, active pulmonary infection, or known hypersensitivity to iloprost or any formulation component. Caution is also advised for individuals with severe hepatic impairment or unstable cardiac conditions.